{"id":486,"date":"2026-01-19T12:40:55","date_gmt":"2026-01-19T11:40:55","guid":{"rendered":"https:\/\/ced-studienzentrum.berlin\/2026\/01\/19\/crohns-disease-fortify-study-risankizumab\/"},"modified":"2026-02-03T11:03:06","modified_gmt":"2026-02-03T10:03:06","slug":"crohns-disease-fortify-study-risankizumab","status":"publish","type":"post","link":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/","title":{"rendered":"Crohn&#8217;s disease: FORTIFY study (Risankizumab)"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; admin_label=&#8221;Listings&#8221; module_id=&#8221;target group&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; background_color=&#8221;#FFFFFF&#8221; background_enable_image=&#8221;off&#8221; background_size=&#8221;custom&#8221; background_image_width=&#8221;90%&#8221; background_position=&#8221;bottom_right&#8221; top_divider_height=&#8221;51px&#8221; locked=&#8221;off&#8221; collapsed=&#8221;on&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_row use_custom_gutter=&#8221;on&#8221; gutter_width=&#8221;3&#8243; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; width=&#8221;100%&#8221; custom_margin=&#8221;|auto|-1px|auto|false|false&#8221; custom_padding=&#8221;||0px||false|false&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;4.18.0&#8243; _module_preset=&#8221;default&#8221; global_colors_info=&#8221;{}&#8221;][et_pb_post_title meta=&#8221;off&#8221; featured_image=&#8221;off&#8221; _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;default&#8221; title_text_color=&#8221;#10344C&#8221; title_font_size=&#8221;45px&#8221; custom_margin=&#8221;||15px|||&#8221; global_colors_info=&#8221;{}&#8221;][\/et_pb_post_title][et_pb_text _builder_version=&#8221;4.27.5&#8243; _module_preset=&#8221;1f09816e-184e-4ce5-a4cf-b39c52c423ca&#8221; text_font=&#8221;&#8211;et_global_body_font||||||||&#8221; text_text_color=&#8221;#10344C&#8221; text_font_size=&#8221;20px&#8221; text_line_height=&#8221;1.8em&#8221; ul_line_height=&#8221;1.8em&#8221; custom_margin=&#8221;||||false|false&#8221; hover_enabled=&#8221;0&#8243; text_font_size_tablet=&#8221;15px&#8221; text_font_size_phone=&#8221;14px&#8221; text_font_size_last_edited=&#8221;on|phone&#8221; header_font_size_tablet=&#8221;55px&#8221; header_font_size_last_edited=&#8221;off|desktop&#8221; global_colors_info=&#8221;{}&#8221; sticky_enabled=&#8221;0&#8243;]This comprehensive study includes several sub-studies to evaluate various aspects of Risankizumab treatment, including maintenance therapy, long-term safety, and patient-reported outcomes. Open-label extensions ensure continuous care for participants.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>This comprehensive study includes several sub-studies to evaluate various aspects of Risankizumab treatment, including maintenance therapy, long-term safety, and patient-reported outcomes. Open-label extensions ensure continuous care for participants.<\/p>\n","protected":false},"author":3,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[38,41],"tags":[],"class_list":["post-486","post","type-post","status-publish","format-standard","hentry","category-for-participants","category-ongoing"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Crohn&#039;s disease: FORTIFY study (Risankizumab) - CED Studienzentrum Karlshorst<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Crohn&#039;s disease: FORTIFY study (Risankizumab) - CED Studienzentrum Karlshorst\" \/>\n<meta property=\"og:description\" content=\"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/\" \/>\n<meta property=\"og:site_name\" content=\"CED Studienzentrum Karlshorst\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T11:40:55+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-03T10:03:06+00:00\" \/>\n<meta name=\"author\" content=\"Pauline Lauterbach\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pauline Lauterbach\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/\"},\"author\":{\"name\":\"Pauline Lauterbach\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"headline\":\"Crohn&#8217;s disease: FORTIFY study (Risankizumab)\",\"datePublished\":\"2026-01-19T11:40:55+00:00\",\"dateModified\":\"2026-02-03T10:03:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/\"},\"wordCount\":244,\"articleSection\":[\"For participants\",\"Ongoing\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/\",\"name\":\"Crohn's disease: FORTIFY study (Risankizumab) - CED Studienzentrum Karlshorst\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\"},\"datePublished\":\"2026-01-19T11:40:55+00:00\",\"dateModified\":\"2026-02-03T10:03:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/crohns-disease-fortify-study-risankizumab\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Start\",\"item\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/ced-study-center-karlshorst\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Crohn&#8217;s disease: FORTIFY study (Risankizumab)\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/\",\"name\":\"CED Studienzentrum Karlshorst\",\"description\":\"Dr. Thomas Brunk\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/#\\\/schema\\\/person\\\/bb726445dbde6c212a82ef1d1ec3fdeb\",\"name\":\"Pauline Lauterbach\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g\",\"caption\":\"Pauline Lauterbach\"},\"url\":\"https:\\\/\\\/ced-studienzentrum.berlin\\\/en\\\/author\\\/paulilauterbachnutzer\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Crohn's disease: FORTIFY study (Risankizumab) - CED Studienzentrum Karlshorst","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/","og_locale":"en_US","og_type":"article","og_title":"Crohn's disease: FORTIFY study (Risankizumab) - CED Studienzentrum Karlshorst","og_description":"Who our studies are suitable forWe conduct clinical studies for individuals with moderate to severe chronic inflammatory bowel diseases. Both early and advanced stages of the disease can be considered. Whether participation is possible always depends on the specific medical inclusion criteria of the study. These will be explained in detail during the information session.Quality [&hellip;]","og_url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/","og_site_name":"CED Studienzentrum Karlshorst","article_published_time":"2026-01-19T11:40:55+00:00","article_modified_time":"2026-02-03T10:03:06+00:00","author":"Pauline Lauterbach","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pauline Lauterbach","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/#article","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/"},"author":{"name":"Pauline Lauterbach","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"headline":"Crohn&#8217;s disease: FORTIFY study (Risankizumab)","datePublished":"2026-01-19T11:40:55+00:00","dateModified":"2026-02-03T10:03:06+00:00","mainEntityOfPage":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/"},"wordCount":244,"articleSection":["For participants","Ongoing"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/","url":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/","name":"Crohn's disease: FORTIFY study (Risankizumab) - CED Studienzentrum Karlshorst","isPartOf":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website"},"datePublished":"2026-01-19T11:40:55+00:00","dateModified":"2026-02-03T10:03:06+00:00","author":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb"},"breadcrumb":{"@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ced-studienzentrum.berlin\/en\/crohns-disease-fortify-study-risankizumab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Start","item":"https:\/\/ced-studienzentrum.berlin\/en\/ced-study-center-karlshorst\/"},{"@type":"ListItem","position":2,"name":"Crohn&#8217;s disease: FORTIFY study (Risankizumab)"}]},{"@type":"WebSite","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#website","url":"https:\/\/ced-studienzentrum.berlin\/en\/","name":"CED Studienzentrum Karlshorst","description":"Dr. Thomas Brunk","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ced-studienzentrum.berlin\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/ced-studienzentrum.berlin\/en\/#\/schema\/person\/bb726445dbde6c212a82ef1d1ec3fdeb","name":"Pauline Lauterbach","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/f53e1cd99af695e65f7049f9a6e8f851d6a975dd071101a4b88873ebace39780?s=96&d=mm&r=g","caption":"Pauline Lauterbach"},"url":"https:\/\/ced-studienzentrum.berlin\/en\/author\/paulilauterbachnutzer\/"}]}},"_links":{"self":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/486","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/comments?post=486"}],"version-history":[{"count":2,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/486\/revisions"}],"predecessor-version":[{"id":494,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/posts\/486\/revisions\/494"}],"wp:attachment":[{"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/media?parent=486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/categories?post=486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ced-studienzentrum.berlin\/en\/wp-json\/wp\/v2\/tags?post=486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}